6533b838fe1ef96bd12a4f9c

RESEARCH PRODUCT

THERAPEUTIC AND COLATERAL EFFECTS OF 25-HYDRXYCHOLECAICI FEROL IN VITAMIN D DEFICIENCY

subject

description

Vitamin D polar metabolite, 25–HCC has been used in 2 infant groups whose ages range from 0–18 months. In the 1st group of 15 infants, all of them suffered from rickets, clinically, biochemistry and radiologically and no prophylactic vitamin D administration could be demonstrated. The control group (15 infants too) was admitted with similar diseases but no one suffered from rickets. Routine determinations for metabolic assesment of Ca phosphoric metabolism were perforaed in plasma and in 240. urine collections, prior and after 25–HCC adBinietration. The rickets group received 20 mcg/day, orally for 20 days and the control 10mcg/day in the same way. The biochemical study demonstrated that both groups were significantly different at the beginning because of plasmatic phosphate and alkaline phosphatase, and in urine because of calciuria and pH(p. 0.05). And neither plasma Ca, nor titrable acidity or ammoniuria were significant. After treatment the rickets group showed a cospicuous normalization of biochemical parameters consistent with the clinical findings. Neverthelees the most important feature was the sharp rise in calcemia and calciuria (p 0.01) in both groups. In the control urine Ca was over 6mg/Kg/day average; with treatment, urine pH differences disappeared. There is as well a therapeutic trial with 8 cases of metabolic rickets.